

David Nanchen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3589401/publications.pdf>

Version: 2024-02-01

73
papers

3,133
citations

257450
24
h-index

161849
54
g-index

74
all docs

74
docs citations

74
times ranked

5554
citing authors

#	ARTICLE	IF	CITATIONS
1	Subclinical Thyroid Dysfunction and the Risk of Heart Failure Events. <i>Circulation</i> , 2012, 126, 1040-1049.	1.6	410
2	Meta-analysis: Subclinical Thyroid Dysfunction and the Risk for Coronary Heart Disease and Mortality. <i>Annals of Internal Medicine</i> , 2008, 148, 832.	3.9	405
3	Gut microbiota-dependent trimethylamine N-oxide in acute coronary syndromes: a prognostic marker for incident cardiovascular events beyond traditional risk factors. <i>European Heart Journal</i> , 2017, 38, ehw582.	2.2	317
4	Comparison of Application of the ACC/AHA Guidelines, Adult Treatment Panel III Guidelines, and European Society of Cardiology Guidelines for Cardiovascular Disease Prevention in a European Cohort. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1416.	7.4	301
5	Subclinical Thyroid Dysfunction and the Risk of Heart Failure in Older Persons at High Cardiovascular Risk. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 852-861.	3.6	178
6	Prevalence and management of familial hypercholesterolaemia in patients with acute coronary syndromes. <i>European Heart Journal</i> , 2015, 36, 2438-2445.	2.2	129
7	Prognostic value of PCSK9 levels in patients with acute coronary syndromes. <i>European Heart Journal</i> , 2016, 37, 546-553.	2.2	120
8	Prognosis of Patients With Familial Hypercholesterolemia After Acute Coronary Syndromes. <i>Circulation</i> , 2016, 134, 698-709.	1.6	99
9	Trimethyllysine, a trimethylamine N-oxide precursor, provides near- and long-term prognostic value in patients presenting with acute coronary syndromes. <i>European Heart Journal</i> , 2019, 40, 2700-2709.	2.2	79
10	Profiling and validation of circulating microRNAs for cardiovascular events in patients presenting with ST-segment elevation myocardial infarction. <i>European Heart Journal</i> , 2017, 38, ehw563.	2.2	77
11	Improved risk stratification of patients with acute coronary syndromes using a combination of hsTnT, NT-proBNP and hsCRP with the GRACE score. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2018, 7, 129-138.	1.0	70
12	Resting Heart Rate and the Risk of Heart Failure in Healthy Adults. <i>Circulation: Heart Failure</i> , 2013, 6, 403-410.	3.9	69
13	Resting heart rate and incident heart failure and cardiovascular mortality in older adults: role of inflammation and endothelial dysfunction: the PROSPER study. <i>European Journal of Heart Failure</i> , 2013, 15, 581-588.	7.1	57
14	Cysteine-rich angiogenic inducer 61 (Cyr61): a novel soluble biomarker of acute myocardial injury improves risk stratification after acute coronary syndromes. <i>European Heart Journal</i> , 2017, 38, 3493-3502.	2.2	46
15	Impact of Carotid Plaque Screening on Smoking Cessation and Other Cardiovascular Risk Factors. <i>Archives of Internal Medicine</i> , 2012, 172, 344.	3.8	39
16	Safety profile of prasugrel and clopidogrel in patients with acute coronary syndromes in Switzerland. <i>Heart</i> , 2015, 101, 854-863.	2.9	38
17	Alcohol drinking, the metabolic syndrome and diabetes in a population with high mean alcohol consumption. <i>Diabetic Medicine</i> , 2010, 27, 1241-1249.	2.3	37
18	Reasons for discontinuation of recommended therapies according to the patients after acute coronary syndromes. <i>European Journal of Internal Medicine</i> , 2015, 26, 56-62.	2.2	37

#	ARTICLE	IF	CITATIONS
19	Resting heart rate: what is normal?. Heart, 2018, 104, 1048-1049.	2.9	36
20	Predictive value of the age, creatinine, and ejection fraction (ACEF) score in patients with acute coronary syndromes. International Journal of Cardiology, 2018, 270, 7-13.	1.7	33
21	Eligibility for PCSK9 inhibitors based on the 2019 ESC/EAS and 2018 ACC/AHA guidelines. European Journal of Preventive Cardiology, 2021, 28, 59-65.	1.8	30
22	Eligibility for PCSK9 Inhibitors According to American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines After Acute Coronary Syndromes. Journal of the American Heart Association, 2017, 6, .	3.7	29
23	Quality of Care after Acute Coronary Syndromes in a Prospective Cohort with Reasons for Non-Prescription of Recommended Medications. PLoS ONE, 2014, 9, e93147.	2.5	28
24	Expected impact of applying new 2013 AHA/ACC cholesterol guidelines criteria on the recommended lipid target achievement after acute coronary syndromes. Atherosclerosis, 2015, 239, 118-124.	0.8	26
25	Prognostic value of elevated lipoprotein(a) in patients with acute coronary syndromes. European Journal of Clinical Investigation, 2019, 49, e13117.	3.4	24
26	Childhood adversity: A gateway to multimorbidity in older age?. Archives of Gerontology and Geriatrics, 2019, 80, 31-37.	3.0	24
27	Inflammation during acute coronary syndromes â€” Risk of cardiovascular events and bleeding. International Journal of Cardiology, 2019, 287, 13-18.	1.7	22
28	Prognosis of cardiovascular and non-cardiovascular multimorbidity after acute coronary syndrome. PLoS ONE, 2018, 13, e0195174.	2.5	21
29	Diabetes and baseline glucose are associated with inflammation, left ventricular function and short- and long-term outcome in acute coronary syndromes: role of the novel biomarker Cyr 61. Cardiovascular Diabetology, 2019, 18, 142.	6.8	21
30	Comparison of Swiss and European risk algorithms for cardiovascular prevention in Switzerland. European Journal of Preventive Cardiology, 2021, 28, 204-210.	1.8	21
31	Low statin use in adults hospitalized with acute coronary syndrome. Preventive Medicine, 2015, 77, 131-136.	3.4	18
32	Uptake and efficacy of a systematic intensive smoking cessation intervention using motivational interviewing for smokers hospitalised for an acute coronary syndrome: a multicentre beforeâ€”after study with parallel group comparisons. BMJ Open, 2016, 6, e011520.	1.9	18
33	Identifying familial hypercholesterolemia in acute coronary syndrome. Current Opinion in Lipidology, 2016, 27, 375-381.	2.7	18
34	Evaluation of contemporary treatment of high- and very high-risk patients for the prevention of cardiovascular events in Europe â€” Methodology and rationale for the multinational observational SANTORINI study. Atherosclerosis Plus, 2021, 43, 24-30.	0.7	17
35	Prognostic value of pulse pressure after an acute coronary syndrome. Atherosclerosis, 2018, 277, 219-226.	0.8	15
36	Health utility indexes in patients with acute coronary syndromes. Open Heart, 2016, 3, e000419.	2.3	14

#	ARTICLE	IF	CITATIONS
37	Novel Blood Biomarkers for a Diagnostic Workup of Acute Aortic Dissection. <i>Diagnostics</i> , 2021, 11, 615.	2.6	14
38	Non-Linear Relationship between Anti-Apolipoprotein A-1 IgGs and Cardiovascular Outcomes in Patients with Acute Coronary Syndromes. <i>Journal of Clinical Medicine</i> , 2019, 8, 1002.	2.4	11
39	Trends in Physical and Cognitive Performance Among Community-Dwelling Older Adults in Switzerland. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2020, 75, 2347-2353.	3.6	11
40	Cardiovascular Risk Estimation and Eligibility for Statins in Primary Prevention Comparing Different Strategies. <i>American Journal of Cardiology</i> , 2009, 103, 1089-1095.	1.6	10
41	Associations Between Cardiovascular Risk Factors, Inflammation, and Progression of Carotid Atherosclerosis Among Smokers. <i>Nicotine and Tobacco Research</i> , 2016, 18, 1533-1538.	2.6	10
42	Improving 1-year mortality prediction in ACS patients using machine learning. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 855-865.	1.0	9
43	Do baby boomers feel healthier than earlier cohorts after retirement age? The Lausanne cohort Lc65+ study. <i>BMJ Open</i> , 2019, 9, e025175.	1.9	8
44	Prognosis of Patients with Chronic and Hospital-Acquired Anaemia After Acute Coronary Syndromes. <i>Journal of Cardiovascular Translational Research</i> , 2020, 13, 618-628.	2.4	8
45	Effectiveness, Adherence, and Safety of Evolocumab in a Swiss Multicenter Prospective Observational Study. <i>Advances in Therapy</i> , 2022, 39, 504-517.	2.9	8
46	Statins for Cardiovascular Prevention According to Different Strategies. <i>American Journal of Cardiovascular Drugs</i> , 2011, 11, 33-44.	2.2	7
47	Thrombus aspiration in acute coronary syndromes: prevalence, procedural success, change in serial troponin T levels and clinical outcomes in a contemporary Swiss cohort. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2018, 7, 522-531.	1.0	7
48	Prognostic values of fasting hyperglycaemia in non-diabetic patients with acute coronary syndrome: A prospective cohort study. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 589-598.	1.0	7
49	Prognostic value of total testosterone levels in patients with acute coronary syndromes. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 235-242.	1.8	7
50	Residual inflammatory risk at 12 months after acute coronary syndromes is frequent and associated with combined adverse events. <i>Atherosclerosis</i> , 2021, 320, 31-37.	0.8	7
51	Public health impact of statin prescribing strategies based on JUPITER. <i>Preventive Medicine</i> , 2011, 52, 159-163.	3.4	6
52	Clinical impact of a structured secondary cardiovascular prevention program following acute coronary syndromes: A prospective multicenter healthcare intervention. <i>PLoS ONE</i> , 2019, 14, e0211464.	2.5	6
53	Optimal Timing of Invasive Coronary Angiography following NSTEMI. <i>Journal of Interventional Cardiology</i> , 2020, 2020, 1-9.	1.2	6
54	CCN family member 1 (CCN1) is an early marker of infarct size and left ventricular dysfunction in STEMI patients. <i>Atherosclerosis</i> , 2021, 335, 77-83.	0.8	6

#	ARTICLE	IF	CITATIONS
55	Mortality Associated with Diabetes and Cardiovascular Disease in Older Women. PLoS ONE, 2012, 7, e48818.	2.5	6
56	Cohort Profile: The Lausanne cohort 65+ (Lc65+). International Journal of Epidemiology, 2022, 51, e156-e166.	1.9	6
57	Intensified lipid lowering using ezetimibe after publication of the IMPROVE-IT trial: A contemporary analysis from the SPUM-ACS cohort. International Journal of Cardiology, 2020, 303, 8-13.	1.7	5
58	Prognostic role of plasma galectin-3 levels in acute coronary syndrome. European Heart Journal: Acute Cardiovascular Care, 2020, 9, 869-878.	1.0	5
59	Impact of malignancy on clinical outcomes in patients with acute coronary syndromes. International Journal of Cardiology, 2021, 328, 8-13.	1.7	5
60	Prognostic value of inflammatory biomarkers and GRACE score for cardiac death and acute kidney injury after acute coronary syndromes. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 445-452.	1.0	5
61	Identification and molecular characterisation of Lausanne Institutional Biobank participants with familial hypercholesterolaemia – a proof-of-concept study. Swiss Medical Weekly, 2016, 146, w14326.	1.6	5
62	Is atherosclerosis imaging the most sensitive way to assess patients' risk and the best way to conduct future drug trials? A pros-and-cons debate. Atherosclerosis, 2017, 266, 229-233.	0.8	4
63	Cysteineâ€Rich Angiogenic Inducer 61 Improves Prognostic Accuracy of GRACE (Global Registry of Acute) Tj ETQq1 1 0.784314 rgBT Heart Association, 2021, 10, e020488.	3.7	4
64	Combining bone resorption markers and heel quantitative ultrasound to discriminate between fracture cases and controls. Osteoporosis International, 2009, 20, 1695-1703.	3.1	3
65	Gender and age differences in outcomes of patients with acute coronary syndromes referred for coronary angiography. Catheterization and Cardiovascular Interventions, 2019, 93, 16-24.	1.7	3
66	Older Peopleâ€™s Health-Related Behaviors: Evidence from Three Cohorts of the Lc65+ Study. Behavioral Medicine, 2020, 47, 1-5.	1.9	2
67	Hospital revascularisation capability and quality of care after an acute coronary syndrome in Switzerland. Swiss Medical Weekly, 2016, 146, w14275.	1.6	2
68	Smoking Cessation in People With and Without Diabetes After Acute Coronary Syndrome. Nicotine and Tobacco Research, 2023, 25, 58-65.	2.6	2
69	Control of cardiovascular risk factors and health behaviors in patients post acute coronary syndromes eligible for protein convertase subtilisin/kexin-9 inhibitors. International Journal of Cardiology, 2020, 299, 289-295.	1.7	1
70	Association between income and control of cardiovascular risk factors after acute coronary syndromes: an observational study. Swiss Medical Weekly, 2019, 149, w20049.	1.6	1
71	Carotid plaque screening as a motivational tool for healthy behavior. American Heart Journal, 2008, 155, e37.	2.7	0
72	Association between self-reported motivation to quit smoking with effectiveness of smoking cessation intervention among patients hospitalized for acute coronary syndromes in Switzerland. Preventive Medicine Reports, 2021, 24, 101583.	1.8	0

#	ARTICLE	IF	CITATIONS
73	Abstract 15491: Effects of Intensive Smoking Cessation Counseling After Acute Coronary Syndrome on 5-year Incidence of Major Adverse Cardiovascular Events and Smoking Abstinence. Circulation, 2020, 142, .	1.6	0